Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of KLAR.ST is 1.00 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell